Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

Short summary

Adding stereotactic ablative radiotherapy (SABR) to standard care significantly improved 5-year overall survival (42.3% vs 17.7%) and progression-free survival (17.3% vs 3.2%) in patients with 1-5 metastases, with no added toxicity or quality-of-life detriment.

AI-generated from the title and abstract; the full text is not read.